INHALED NO FOR THE PREVENTION AND TX OF CHRONIC LUNG DISEASE IN PRETERM INFNT

这个子项目是许多研究子项目中利用 资源由NIH/NCRR资助的中心拨款提供。子项目和 调查员(PI)可能从NIH的另一个来源获得了主要资金， 并因此可以在其他清晰的条目中表示。列出的机构是 该中心不一定是调查人员的机构。 早产儿慢性肺病(CLD)已成为美国最常见、最致命、最昂贵的新生儿肺部疾病。据估计，全国的流行率为10,000-15,000例。目前预防和治疗婴儿肺部疾病的治疗方法，包括产前皮质类固醇治疗、表面活性物质替代以及出生后给予类固醇、维生素A、利尿剂和支气管扩张剂，并未导致CLD的临床显著减少。患有最严重的慢性阻塞性肺疾病的婴儿会出现呼吸道阻力增加，其结果与肺原性心脏病的肺动脉高压相一致。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Chronic lung disease (CLD) of prematurity has emerged as the most common, lethal and expensive remaining neonatal pulmonary disorder in the United States. The estimated prevalence is 10,000-15,000 cases in the nation. Current therapeutic approaches to prevention and treatment of lung disease of infants, which include antenatal corticosteroid treatment, surfactant replacement, and postnatal administration of steroids, Vitamin A, diuretics and bronchodilators, have not resulted in clinically significant decreases in CLD. Infants with the most severe forms of CLD develop increased airway resistance and findings consistent with pulmonary hypertension with corpulmonale.